To assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing–remitting multiple sclerosis (RRMS). This evidence concerns the gene GDI1 and relapsing-remitting multiple sclerosis.